Clinical trials: Regorafenib
Metastatic Colorectal Cancer
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
This is an observational study in which data already collected from people with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part…
- Trial name
- RegoSeq (NCT06137170)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Advanced Hepatocellular Carcinoma
A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
- Trial name
- NCT05773105
- Testing
- Cadonilimab+regorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Colorectal Carcinoma
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
This is a multicenter observational study aimed to describe the efficacy and safety of regorafenib plus programmed cell death-1 (PD-1) inhibitors in Chinese patients with advanced colorectal cancer in routine clinical practice.
- Trial name
- NCT04771715
- Testing
- Regorafenib, Nivolumab, Pembrolizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Neoplasms, Metastatic Disease
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
- Trial name
- REFRAME (NCT01875380)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Neoplasms
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
This multi-center, open-label, non-randomized, non-placebo-controlled, Phase I study will define the safety profile and tumor response profile of the multi-kinase inhibitor BAY73-4506 as oral treatment in combination with the…
- Trial name
- NCT00934882
- Testing
- Regorafenib (BAY73-4506)
- Where
- 7 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Bayer
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Advanced Chemorefractory Colorectal Adenocarcinoma
Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
The general objectives are to evaluate activity and the safety of regorafenib in a population of patients bearing advanced, refractory colorectal cancers and to explore the different downstream molecular pathways to identify…
- Trial name
- RegARd-C (NCT01929616)
- Testing
- regorafenib
- Where
- 17 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- Jules Bordet Institute
Unresectable Locally Advanced or Metastatic Solid Tumors
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort…
- Trial name
- NCT06682611
- Testing
- SYHA1813, SG001, HB1801
- Volunteers
- 380 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Cholangiocarcinoma
Regorafenib Versus Placebo to Treat Cholangiocarcinoma
The study is a multicenter randomized (1:1) placebo-controlled, double-blinded phase II trial aiming to demonstrate an improvement of median PFS when treating locally advanced unresectable or metastatic patients suffering from an…
- Trial name
- REACHIN (NCT02162914)
- Testing
- Regorafenib/active
- Where
- 12 sites in Belgium
- Volunteers
- 66 people
- Sponsor
- Erasme University Hospital
Carcinoma, Hepatocellular, Lenvatinib
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
The purpose of this clinical trial is to evaluate the efficacy and safety of regorafenib as a subsequent therapy for patients with hepatocellular carcinoma (HCC) who have failed prior lenvatinib treatment.
- Conditions
- Carcinoma, Hepatocellular, Lenvatinib, Treatment Failure
- Trial name
- RELEVANT-HCC (NCT07514429)
- Testing
- Regorafenib (BAY 73-4506)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Ju Hyun Shim
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Hepatocarcinoma
Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib
The aim of this trial is to investigate whether quantitative analysis of the total concentration of circulating free deoxyribonucleic acid (cfDNA) and of the cfDNA integrity index (DII) (Intplex®) may reflect hepatocellular…
- Trial name
- HELP (NCT03956940)
- Testing
- Intplex test
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST)
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically…
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
- Trial name
- NCT05489237
- Testing
- IDRX-42
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 276 people
- Sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Neoplasms
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
- Trial name
- NCT01973868
- Testing
- Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
Regorafenib is an oral tumour deactivation agent that potently blocks multiple protein kinases, including kinases involved in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis…
- Trial name
- GOING (NCT04170556)
- Testing
- Regorafenib, Nivolumab
- Where
- 7 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Metastatic Colorectal Cancer
An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe
This is an observational study in which data from patients with metastatic colorectal cancer in three European countries who received STIVARGA® (regorafenib), are collected.
- Trial name
- RegoFlex EU (NCT05551039)
- Testing
- Retrospective patient chart review
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bayer